Not a good buy right now: price action and momentum are bearish, and probabilistic pattern analysis also points to further downside over the next day/week/month.
Even though Street sentiment has recently improved (two Buys in Jan-2026), the stock is trading below key support and lacks a confirming reversal signal.
Near-term catalyst risk is high with Q4/FY25 results on Mar 10–11; for an impatient buyer, the current setup is not favorable.
Trend: Bearish (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend across long/medium/short timeframes.
Momentum: MACD histogram at -0.0432 and negatively expanding → downside momentum is strengthening, not fading.
RSI: RSI_6 at 28.46 suggests the stock is approaching oversold conditions (potential for a short bounce), but it is not yet a confirmed reversal.
Levels: Pre-market 4.67 is below S1 (4.772) and closer to S2 (4.514) → price is trading in a weak zone; meaningful recovery would require reclaiming Pivot ~5.19, then R1 ~5.61.
Pattern-based outlook: Similar-pattern model implies ~70% odds of mild additional declines (next day/week/month).
Positive Catalysts
could reset expectations if Mexico normalization shows up in numbers/guidance.
Profitability: Net income 48,094,000 (down -50.87% YoY) and EPS 0.65 (down -50.76% YoY) → sharp earnings deterioration.
Margins: Gross margin 37.52% (down -5.92% YoY) → margin compression is a key issue and aligns with the bearish price trend.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: improving.
2025-11-18: JPMorgan downgraded to Neutral (PT cut to $6 from $13.50) citing slower Mexico ramp and elevated leverage.
2026-01-16: Jefferies initiated Buy (PT $9) arguing the stock is at a “deep discount” with growth re-acceleration potential as Mexico normalizes.
2026-01-20: HSBC upgraded to Buy (PT $6.90).
Wall Street pros: Potential re-rating pathway; normalization in Mexico could re-accelerate growth.
Wall Street cons: Execution risk in Mexico ramp, leverage remaining elevated, and a less compelling consolidated growth profile recently.
Wall Street analysts forecast AUNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUNA is 6 USD with a low forecast of 6 USD and a high forecast of 6 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast AUNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUNA is 6 USD with a low forecast of 6 USD and a high forecast of 6 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 4.510
Low
6
Averages
6
High
6
Current: 4.510
Low
6
Averages
6
High
6
BTG Pactual
Samuel Alves
Buy -> Neutral
downgrade
$7
AI Analysis
2026-02-05
New
Reason
BTG Pactual
Samuel Alves
Price Target
$7
AI Analysis
2026-02-05
New
downgrade
Buy -> Neutral
Reason
BTG Pactual analyst Samuel Alves downgraded Auna to Neutral from Buy with a $7 price target.
HSBC
Hold
to
Buy
upgrade
$6.90
2026-01-20
Reason
HSBC
Price Target
$6.90
2026-01-20
upgrade
Hold
to
Buy
Reason
HSBC upgraded Auna to Buy from Hold with a $6.90 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for AUNA